Table 2.
Comparison of clinical and CMR parameters between 6-month survivors and non-survivors with cardiac amyloidosis
| Characteristic | Survivors (n = 30) | Non-survivors (n = 17) | P value |
|---|---|---|---|
| Demographics | |||
| Age (years) | 61 ± 10 | 59 ± 11 | 0.462 |
| Male [n (%)] | 19 (63.3%) | 9 (59.2) | 0.255 |
| NYHA class | 2.0 (1.0–3.0) | 3.0 (2.0–4.0) | 0.026 |
| Low voltage [n (%)] | 14 (46.7%) | 11 (64.7%) | 0.362 |
| Chemotherapy [n (%)] | 11 (36.7%) | 3 (17.6%) | 0.204 |
| Biochemical biomarkers | |||
| κ:λ ratio | 1.5 ± 1.0 | 1.4 ± 0.7 | 0.678 |
| Troponin T (ng/L) | 49.1 (25.5–116.4) | 61.0 (61.0–209.4) | 0.023 |
| NT-proBNP (pg/ml) | 4087 (1534–7872) | 8338 (3820–14248) | 0.058 |
| Creatinine (μmol/L) | 73.9 (52.9–104.4) | 94.9 (69.4–136.0) | 0.022 |
| AST (IU/L) | 25.0 (20.0–37.0) | 34.5 (26.3–44.0) | 0.031 |
| ALT (IU/L) | 22.0 (13.0-35.0) | 25.0 (21.0–37.0) | 0.227 |
| UA (μmol/L) | 393 (354.5–495.3) | 485.5 (408.5–617.3) | 0.062 |
| CMR volume | |||
| LVEF (%) | 48 ± 12 | 44 ± 11 | 0.186 |
| LVEDVi (mL/m2) | 74 ± 20 | 71 ± 17 | 0.622 |
| LVESVi (mL/m2) | 38 ± 15 | 40 ± 13 | 0.654 |
| LVMI | 85 ± 31 | 105 ± 27 | 0.031 |
| RVEF (%) | 48 ± 14 | 38 ± 13 | 0.021 |
| RVEDVi (mL/m2) | 61 ± 19 | 69 ± 20 | 0.201 |
| RVESVi (mL/m2) | 31 ± 12 | 43 ± 15 | 0.008 |
| LV-LGE [n (%)] | 22 (73.3%) | 17 (100%) | 0.038 |
| RV-LGE [n (%)] | 13 (43.3%) | 14 (82.4%) | 0.015 |
AST aspartate aminotransferase, ALT alanine aminotransferase, UA uric acid, LGE late gadolinium enhancement